Bioretec receives FDA breakthrough device designation for spinal interbody cage

Bioretec received FDA breakthrough device designation for its RemeOs spinal interbody cage, designed to restore intervertebral height during cervical spinal fusion. Timo Lehtonen, CEO of Bioretec, expressed excitement about the market opportunities for the product, based on patented hybrid technology. This designation validates the company’s expertise in creating innovative orthopedic products to meet clinical needs.

Source link

error: Content is protected !!